There are 2789 resources available
1250P - Differences of immune microenvironment among NSCLC patients with various KRAS mutation types
Presenter: Kun Wang
Session: ePoster Display
1252P - Liquid biopsy to track KRAS G12C mutation at progressive disease in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: Gianluigi De Renzi
Session: ePoster Display
1254P - Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC
Presenter: Marina Chiara Garassino
Session: ePoster Display
1255P - Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
Presenter: Niels Reinmuth
Session: ePoster Display
1256P - Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial
Presenter: Rebecca Heist
Session: ePoster Display
1257P - Effect of hepatic impairment on tepotinib pharmacokinetics
Presenter: Thomas Marbury
Session: ePoster Display
1258P - MET exon14 skipping in non-small cell lung cancer: Clinicopathological characteristics, treatments, and efficacy of crizotinib according to functional analysis: AFonMET - GFPC study
Presenter: Hélène Babey
Session: ePoster Display
1259P - Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
Presenter: Xiuning Le
Session: ePoster Display
1260P - Clinical outcomes of patients with BRAF<sup>v</sup>⁶⁰⁰-mutated metastatic NSCLC (mNSCLC) receiving first-line (1L) dabrafenib-trametinib vs other standard of care in real-world practice
Presenter: Barbara Melosky
Session: ePoster Display
1307P - Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1–positive (TPS ≥50%), advanced NSCLC in Japan
Presenter: Yasushi Goto
Session: ePoster Display